Close Menu

NEW YORK (GenomeWeb) – BG Medicine's stock was down as much as 43 percent in morning trading on the OTC market following the company's announcement today that it has withdrawn its 510(k) premarket notification with the US Food and Drug Administration for an expanded indication of its BGM Galectin-3 test.

BG had hoped to obtain 510(k) clearance for use of the test in assessing the near-term risk of fatal cardiovascular events in older adults with no prior history of cardiovascular disease, cerebrovascular disease, or vascular disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
29
Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.